Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Pathophysiological Effects of Lycosa erythrognatha Derived Peptide LyeTxI-b on RKO-AS-45-1 Colorectal Carcinoma Cell Line Using the Chicken Chorioallantoic Membrane Model

Full text
Author(s):
da Silva, Carolina Nunes [1] ; Nunes Dourado, Lays Fernanda [1] ; Silva, Luciana Maria [2] ; de Lima, Aline Brito [2] ; de Lima, Maria Elena [3] ; Silva-Cunha, Armando [1] ; Ligorio Fialho, Silvia [2, 4]
Total Authors: 7
Affiliation:
[1] Univ Fed Minas Gerais, Fac Farm, Campus Pampulha, Av Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG - Brazil
[2] Fundacao Ezequiel Dias, Diretoria Pesquisa & Desenvolvimento, Rua Conde Pereira Carneiro 80, BR-30510010 Belo Horizonte, MG - Brazil
[3] Santa Casa Belo Horizonte Inst Ensino & Pesquisa, BR-30150221 Belo Horizonte, MG - Brazil
[4] Rua Conde Pereira Carneiro 80, BR-30510010 Belo Horizonte, MG - Brazil
Total Affiliations: 4
Document type: Journal article
Source: INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS; v. 28, n. 1 JAN 2022.
Web of Science Citations: 0
Abstract

The synthetic peptide derived from a spider toxin, Lycosa erithrognatha, LyeTxI-b, has known antitumoral and antiangiogenic activity. So, in this study we evaluated their effect on colorectal cancer (CRC), using the chicken chorioallantoic membrane (CAM) model for tumor development. On the 11th day of embryo development, the eggs were opened and the cell culture of RKO-AS-45-1 was instilled on the CAM surface and the eggs were reincubated for more 48 h. Sequentially, the LyeTxI-b was applied over the CAM. Cisplatin and phosphate-buffered saline (PBS) pH 7.4 were used as positive and negative controls, respectively (n = 6). On the 14th day of embryo development, the CAM was photographed and samples were analyzed by histology and immunohistochemistry. Lastly, the vessels around the tumor were quantified and CAM network topography analyzed. Tumor area in CAM that received LyeTxI-b showed a reduction similar to Cisplatin-treated, proven by histological analysis. Immunohistochemistry analysis showed the expression of hCDC47 in the CAM with colorectal tumor was lower after treatment with LyeTxI-b or Cisplatin. Also, LyeTxI-b or cisplatin treated CAM showed a significant reduction in area of vascularization in comparison to the vehicle-treated group. Using the CAM model it was possible to evaluate the efficacy of LyeTxI-b as a potent antitumor agent in CRC, quickly and effectively and in agreement to 3r's principle: to replace, reduce or refine the use of animals in experimentation. (AU)

FAPESP's process: 14/50928-2 - INCT 2014: Pharmaceutical Nanotechnology: a transdisciplinary approach
Grantee:Maria Vitória Lopes Badra Bentley
Support Opportunities: Research Projects - Thematic Grants